Published in TB and Outbreaks Week, September 9th, 2003
The company also provided an update on development programs involving its proprietary eligen oral drug delivery technology.
"Most notably in the second quarter, we executed on our key strategic objective of creating improved dosage forms of our lead product candidates," commented Michael M. Goldberg, MD, chairman and CEO of Emisphere. "During the second quarter we created enhanced dosage forms of both insulin or heparin and synthesized clinical supplies in our newly validated manufacturing facility."
He continued: "We also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week